Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,236 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,066
- Phase 1823
- Phase 1/Phase 2446
- Phase 3426
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis345
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama179
- Arizona141
- Florida141
- New York122
- Massachusetts120
- Texas119
- Illinois82
- Colorado77
Recruiting studies6,236 total
- NCT04077307RecruitingPhase 1
Karonudib for leukemia that has come back or not responded
This Phase 1 trial studies Karonudib, a new treatment, for people with leukemia (and a few related blood cancers) that has come back or didn’t respond to standard care. The goal is to see if the treatment is safe and to learn how it may work in this hard-to-treat setting.
AarhusAges 18–75 - NCT07284758RecruitingPhase 2
Cemsidomide and dexamethasone for relapsed/refractory multiple myeloma
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
Huntsville, AlabamaAges 18 years+ - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Little Rock, ArkansasAges 2–11 - NCT07222332RecruitingPhase 3
Baricitinib for new type 1 diabetes to save insulin-making cells
This trial tests if baricitinib, a pill that calms the immune system, can protect the remaining insulin-making cells in people newly diagnosed with type 1 diabetes. If it works, you might keep making some of your own insulin longer.
Aurora, ColoradoAges 1–35 - NCT06832306Recruiting
Diaphragm pacing for breathing support in ICU
This trial tests a device that helps stimulate the diaphragm to improve breathing in patients who need a ventilator. It's for people with new breathing problems who have been in the ICU on a ventilator for less than 4 days.
La Jolla, CaliforniaAges 18 years+ - NCT07579741RecruitingPhase 1/Phase 2
Testing JL18008 for HIV Patients Not Recovering Immune Cells
This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.
Beijing, Beijing MunicipalityAges 18–65 - NCT06090864RecruitingPhase 1/Phase 2
Engineered immune cells for Hodgkin lymphoma
This trial tests a new treatment where your own immune cells are modified to better attack Hodgkin lymphoma cells. It is for people whose disease has not responded to other therapies.
Chapel Hill, North CarolinaAges 18 years+ - NCT05976763RecruitingPhase 3
Testing continuous vs. intermittent zanubrutinib for older adults with mantle cell lymphoma
This trial tests whether taking the targeted drug zanubrutinib continuously is better than taking it on a schedule with breaks for older adults with untreated mantle cell lymphoma. The goal is to find a treatment that works while reducing side effects.
Little Rock, ArkansasAges 60 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Gilbert, ArizonaAges 18 years+ - NCT07750249Enrolling by invitationEarly Phase 1
Short-chain fatty acids for IgA nephropathy
This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.
MartinAges 18 years+ - NCT07290803Recruiting
Atopic dermatitis treatment registry for teens and adults
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Birmingham, AlabamaAges 12 years+ - NCT07564596RecruitingPhase 1/Phase 2
A Study of Budoprutug for Systemic Lupus Erythematosus
This trial tests budoprutug, an experimental drug, to see if it helps people with systemic lupus erythematosus (SLE) whose disease is not well controlled by current treatments. The drug targets immune cells that may be driving the disease.
Mianyang, SichuanAges 18–65 - NCT07223697RecruitingPhase 2
Long-term safety of Afimkibart for eczema patients
This study tests the long-term safety and effectiveness of a medicine called Afimkibart for people with atopic dermatitis (eczema). It is for people who already completed a previous study of this medicine and had at least a 50% improvement in their eczema.
Los Angeles, CaliforniaAges 18 years+ - NCT07643766RecruitingPhase 2
Testing ENV-294 for moderate-to-severe atopic dermatitis
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
Encinitas, CaliforniaAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Birmingham, AlabamaAges 18 years+ - NCT06600568Recruiting
New treatment for T-cell cancers
This trial is testing a new approach to treat T-cell cancers (leukemia and lymphoma). It may be an option for adults with these cancers who are otherwise in reasonably good health.
NaplesAges 18 years+ - NCT05990465RecruitingPhase 1
LV20.19 CAR T-cells plus pirtobrutinib for relapsed B-cell lymphoma
This trial combines a new type of CAR T-cell therapy (LV20.19) with a targeted pill called pirtobrutinib to treat B-cell lymphomas that have come back or stopped responding. The goal is to see if this combination works better than each alone.
Milwaukee, WisconsinAges 18–81 - NCT05564936RecruitingTeam says not enrolling
Digital tests for generalized myasthenia gravis using a smartphone
This study tests a smartphone-based digital tool that helps check symptoms in people with generalized myasthenia gravis (MG). It may help patients and clinicians track how the disease is doing over time using simpler, repeated assessments.
Aurora, ColoradoAges 18 years+ - NCT07068126Recruiting
New treatment for kids with lasting ITP
This trial tests a new approach for children ages 1 to 10 who have had ITP for 3–12 months. It aims to find a better way to manage the condition and improve platelet counts.
AsyutAges 1–10 - NCT07087314RecruitingPhase 2
Study of an injection for nephrotic syndrome in children
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
Hangzhou, ZhejiangAges 6–18 - NCT07060716Recruiting
Blood test to monitor kidney transplant health
This study is testing a blood test that looks for tiny pieces of the donor's DNA in your blood to check how your new kidney is doing. It may help doctors monitor your transplant and spot problems early, possibly without needing a biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT07002710Recruiting
Long-term ventilation and inflammation study
This study looks at how long-term inflammation affects the breathing of people who have been on a ventilator for 10 days or more. It aims to help doctors better understand and support your recovery.
TaipeiAges 20 years+ - NCT06946745Recruiting
Studying IBI363 combo for advanced colorectal cancer
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
BeijingAges 18–75 - NCT06936566RecruitingPhase 2
Ruxolitinib for graft-versus-host disease after transplant
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
Duarte, CaliforniaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,236 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,675 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.